Mabwell Bioscience (688062.SH) subsidiary Lianwei Chuangyuan plans to bring in investors, aiming to promote the development of its innovative drug business.

Zhito Finance APP News, Mabwell (688062.SH) announced that, in accordance with Mabwell's strategic development plan, in order to further promote the company's innovative drug business and focus on technological innovation and industrialization in the next-generation T cell engager field, the company intends to sign a "Capital Increase Agreement" and a "Project Transfer Contract" with its wholly-owned subsidiary Lianwei Chuangyuan (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Lianwei Chuangyuan" or the "Target Company"). The company intends to use monetary funds of RMB 825 million to subscribe to RMB 82.5 million of newly added registered capital of Lianwei Chuangyuan, and confirms that the initial registered capital of Lianwei Chuangyuan of RMB 100,000 corresponds to a capital contribution of RMB 1 million.